These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 9322882)

  • 1. An overview of cyclophosphamide and ifosfamide pharmacology.
    Fleming RA
    Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.
    Wagner A; Hempel G; Boos J
    Anticancer Drugs; 1997 Jun; 8(5):419-31. PubMed ID: 9215603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
    Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS; Jounaidi Y; Waxman DJ
    Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question.
    Williams ML; Wainer IW
    Curr Pharm Des; 1999 Aug; 5(8):665-72. PubMed ID: 10469897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of ifosfamide.
    Furlanut M; Franceschi L
    Oncology; 2003; 65 Suppl 2():2-6. PubMed ID: 14586139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
    Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
    Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
    Blomgren H; Hallström M
    Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and pharmacokinetics of oxazaphosphorines.
    Boddy AV; Yule SM
    Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
    Zhang J; Tian Q; Chan SY; Duan W; Zhou S
    Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecotoxicity and genotoxicity of cyclophosphamide, ifosfamide, their metabolites/transformation products and their mixtures.
    Česen M; Eleršek T; Novak M; Žegura B; Kosjek T; Filipič M; Heath E
    Environ Pollut; 2016 Mar; 210():192-201. PubMed ID: 26735164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
    Opydo-Chanek M; Mazur L; Stojak M
    Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
    Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
    Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
    Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
    J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
    Kerbusch T; de Kraker J; Keizer HJ; van Putten JW; Groen HJ; Jansen RL; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2001 Jan; 40(1):41-62. PubMed ID: 11236809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glufosfamide as a new oxazaphosphorine anticancer agent.
    Mazur L; Opydo-Chanek M; Stojak M
    Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tests of biodegradation of cytostatics cyclophosphamide and ifosfamide using the Closed Bottle Test (OECD 301 D)].
    Kümmerer K; Steger-Hartmann T; Baranyai A; Bürhaus I
    Zentralbl Hyg Umweltmed; 1996 Feb; 198(3):215-25. PubMed ID: 9376051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxicity during ifosfamide treatment in children.
    Di Cataldo A; Astuto M; Rizzo G; Bertuna G; Russo G; Incorpora G
    Med Sci Monit; 2009 Jan; 15(1):CS22-5. PubMed ID: 19114973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide--pharmacologic overview.
    Sarosy G
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):2-8. PubMed ID: 2649983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.